Startseite Meta-analysis of clinical efficacy and safety of immunotherapy combined with chemotherapy in non-small cell lung cancer
Artikel Open Access

Meta-analysis of clinical efficacy and safety of immunotherapy combined with chemotherapy in non-small cell lung cancer

  • Wugang Zhu , Wenjing Xu , Degan Liu , Lei Wan und Xiaolan Lu EMAIL logo
Veröffentlicht/Copyright: 7. August 2025

Abstract

Purpose

This study aimed to assess the clinical effectiveness and safety of combining immunotherapy with chemotherapy for non-small cell lung cancer.

Methods

A comprehensive search of studies published until January 2024 was conducted. Quality assessment was performed using the NOS scale, and a meta-analysis was carried out with RevMan 5.4.1 software. Heterogeneity was assessed using the Q-test, and combined effects were calculated with fixed or random effects models. Results were visualized using forest plots, and a sensitivity analysis was performed.

Results

Out of 1,061 sources, 11 met the inclusion criteria. The meta-analysis indicated that the combination treatment significantly improved 1-year overall survival, objective response rate, and disease control rate compared to chemotherapy alone (P < 0.05), with no significant difference in adverse reactions (P > 0.05). Immune function markers CD4+ and CD4+/CD8+ were higher, and CD8+ was lower in the combined treatment group. Sensitivity analysis confirmed the stability and reliability of the results (OR (95% CI) 3.72 (2.34–5.90), P < 0.00001), although publication bias was indicated by funnel plots.

Conclusion

The combination of chemotherapy and immunotherapy exhibits the potential to enhance both survival rates and clinical effectiveness, without the concomitant rise in severe adverse reactions.

1 Introduction

Recently, a large number of clinical trials have verified the efficacy and safety of immunotherapy in malignant tumors, such as tumor-infiltrating lymphocytes, transgenic T lymphocytes expressing antigen-specific T cell receptors or chimeric antigen receptors, natural killer cells, cytokine-induced killer cells, and dendritic cells, providing new therapeutic strategies for hematological and solid tumors. Based on the data published by the World Health Organization’s International Agency for Research on Cancer in 2023 [1], although lung cancer incidence has decreased globally, it remains the leading cause of cancer-related deaths, comprising approximately 18% of the total number of fatalities [2]. Notably, China recorded approximately 787,000 new cases of lung cancer in 2015, which is equivalent to over 2,100 new cases per day [3]. Among the various types of lung cancer, non-small cell lung cancer (NSCLC) dominates, representing approximately 85% of all cases [2].

Despite the availability of various treatment options for lung cancer, such as surgical resection, chemotherapy, radiotherapy, and targeted therapy, their overall clinical efficacy remains unsatisfactory, leading to a poor prognosis. Five-year survival rates after treatment are less than 15% [2]. Furthermore, many tumors are diagnosed at advanced stages, missing the optimal window for surgical intervention and leaving patients with limited options, such as chemotherapy. Unfortunately, these treatments often come with significant adverse reactions that cause irreversible harm to patients [4,5]. In recent years, the emergence of tumor immunotherapy, specifically through the use of immune checkpoint inhibitors like programmed cell death protein-1 or programmed cell death-ligand 1, and cytotoxic T lymphocyte-associated antigen 4, has shown promising results. These inhibitors effectively modulate excessive immune responses induced by tumors, thereby promoting long-term anti-tumor effects, leading to improved disease response rates and outcomes for patients [611]. Although some studies have indicated the superiority of combining immunotherapy with chemotherapy over chemotherapy alone for NSCLC patients [1216], these studies often suffer from limitations such as small sample sizes, retrospective design, and lack of large-scale clinical trials. Therefore, the application of meta-analysis methods becomes crucial in quantitatively assessing the efficacy and safety of combining immunotherapy with chemotherapy for NSCLC treatment, providing a solid evidence-based foundation for clinical decision-making.

2 Materials and methods

2.1 Sources of materials and retrieval strategies

In order to gather relevant information, a comprehensive computerized search was performed using several databases including China Knowledge Net, Wanfang, Weipu Chinese scientific journals, Chinese Biomedicine, PubMed, Web of science, Cochrane library, etc. The search period covered the database establishment date up until November 2023. The search strategy in Chinese included the keywords “immunotherapy,” “chemotherapy,” “non-small cell lung cancer,” and “curative effect,” while synonyms were also considered. Similarly, the English search strategy involved the terms “immunotherapy,” “chemotherapy,” “non-small cell lung cancer,” and “curative effect.”

2.2 Inclusion and exclusion criteria

Criteria for literature inclusion: (1) patients included in the study were diagnosed with NSCLC; (2) the experimental group received a combination of immunotherapy and chemotherapy, while the control group received chemotherapy alone. There were no restrictions on the specific types and treatment regimens of immunotherapy and chemotherapy; (3) the outcome measures assessed were overall survival (OS), objective response rate (ORR), disease control rate (DCR), adverse reactions, CD4+, CD8+, and CD4+/CD8+; and (4) in case of multiple publications by the same author reporting the same data, the study with the largest sample size or the most recent publication were chosen.

The following criteria were applied to the exclusion of literature: (1) removal of duplicate and irrelevant studies as well as review literature; (2) exclusion of non-randomized controlled trials; (3) elimination of studies with inconsistent outcome indicators; (4) exclusion of trials where the experimental group does not receive immunotherapy combined with chemotherapy or the control group receives chemotherapy alone; (5) omission of studies with missing, incomplete, unavailable, or obviously incorrect data; and (6) exclusion of literature studies conducted before 2020 with a sample size smaller than 70.

2.3 Literature screening and data extraction

Two researchers from the research team conducted a thorough review of the literature using predefined inclusion and exclusion criteria. Initially, they assessed the titles and abstracts of the articles and, if necessary, proceeded to examine the full text. In cases where there were discrepancies, they consulted external experts to reach a consensus. Articles that met the inclusion criteria were carefully analyzed using a pre-established literature characteristics table to extract pertinent information. This included details such as study design, total sample size, sample size of the experimental group, sample size of the control group, and outcome measures, among others.

2.4 Literature quality evaluation

In order to assess the methodological quality, we utilized the Newcastle-Ottawa quality assessment scale (NOS). The scoring system ranged from 0 to 9, where scores falling within the range of 7–9 were indicative of high methodological quality (grade A), scores ranging from 4 to 6 reflected fair methodological quality (grade B), and scores below 4 indicated low methodological quality (grade C).

2.5 Statistical methods

Literature management was conducted using Note Express 3.2 software, while Excel2003 software was utilized for literature data collection and extraction. Revman 5.4.1 software was employed for performing the meta-analysis. Heterogeneity analysis was conducted on the extracted data using the Q-test (P-value), with the addition of the I 2 value to assess heterogeneity. In the case where P > 0.10 or I 2 ≤ 50%, indicating the absence of heterogeneity, a fixed-effect model (FEM) was applied. In contrast, if heterogeneity was present, a random-effects model (REM) was used. At the same time, the source of literature heterogeneity was explored by deleting the literature with the largest proportion of weight. The pooled results of the meta-analysis were described using the odds ratio (OR) and its corresponding 95% confidence interval (CI), while illustrating forest plots. Sensitivity analysis was conducted to assess the stability of the meta-analysis results, and publication bias was evaluated through the use of funnel plots. The significance level for testing was set at α = 0.05 (two-sided).

3 Results

3.1 Literature search results

Based on the article search strategy, a total of 1,061 pertinent documents were initially retrieved from various databases such as China Knowledge Net, Wanfang Database, VIP Chinese Science and Technology Journal Database, China Biomedical Database, PubMed, Web of Science, Cochrane library, among others. To eliminate duplicate literature, duplicates found in multiple databases were removed. Subsequently, through careful examination of title, abstract, and full text, 11 pertinent literatures were ultimately included in the study. The literature screening process is illustrated in Figure 1.

Figure 1 
                  Flow chart of literature screening.
Figure 1

Flow chart of literature screening.

3.2 Basic characteristics and quality evaluation of literature

The baseline data comprise primarily information such as gender, age, disease duration, treatment plan, and outcome measures. A comprehensive overview of the baseline data can be found in the 11 literature sources included in this study. The quality of the 11 selected studies is assessed using the NOS scale, with the results presented in Table 1 [1727].

Table 1

Basic characteristics and quality evaluation table of literature

First author Year of publication Sample size (example) Age Intervention measures Outcome index NOS
Test group Control group Control group Test group
He Jing [17] 2022 150 130 40 years old and 80 years old PD-1/PD-L1 immunization combined with docetaxel chemotherapy Docetaxel chemotherapy ①→④⑤⑥⑦⑧ 5
Yang Juyin [18] 2023 40 40 / Single chemotherapy group combined with PD-1/PD-L1 inhibitor AP regimen containing platinum (pemetrexed + platinum) or TP regimen (paclitaxel + platinum) ②→③ 5
Zhao Jingjing [19] 2022 44 44 24 years old and 71 years old DC/CIK immunotherapy was performed on the basis of simple chemotherapy Simple chemotherapy ③→③⑥⑦⑧ 5
Sun Liling [20] 2023 38 44 18 years old, 75 years old Carrell monoclonal antibody combined with platinum-containing double drugs Platinum-containing dual drug therapy ①→②③④⑥⑦⑧ 6
Li et al. [21] 2023 50 50 60–83 years old Carrilizumab combined with chemotherapy Chemotherapy ④→ 5
Chen Min [22] 2023 52 52 Test group: 60.47 ± 5.13; control group: 61.58 ± 5.44 Chemotherapy group was immunized with pablizumab on the basis of chemotherapy Give ②→③④⑥⑧ 6
Sun Xiongying [23] 2022 36 35 The experimental group: 68.13 ± 4.28; the control group: 68.35 ± Immunotherapy combined with chemotherapy Platinum-containing dual-drug chemotherapy ⑤→⑧ 5
He Siyi [24] 2021 35 35 4.32 Albumin paclitaxel + xindiril monoclonal antibody Simple chemotherapy ③→③⑥⑦⑧ 5
Pan Enyuan [25] 2021 40 40 Experimental group: 57.12 ± On the basis of chemotherapy, combined with bevacizumab Albumin paclitaxel chemotherapy regimen ⑥→⑧ 5
Shiyuan Garden [26] 2023 38 35 7.05; control group: 56.41 ± 7.14 Chemotherapy plus immunotherapy Pemetrexed plus platinum chemotherapy ④→ 5
Zhang Jingbao [27] 2022 75 75 / A single bead for Riley Simple chemotherapy ②③⑤⑥⑦⑧ 5

Notes: ① 1 years of OS, ② ORR, ③ DCR, ④ PFS, ⑤ adverse reactions, ⑥ CD4+, ⑦ CD8+, ⑧ CD4+/CD8+.

3.3 Meta-analysis results

3.3.1 Clinical efficacy

3.3.1.1 One-year OS

Two literature reviews were conducted to compare the OS rates of patients in the experimental and control groups over a period of 1 year. The test group consisted of 188 cases, while the control group had 174 cases. Statistical heterogeneity tests were performed on the included literature, and the results indicated no significant variation across different studies. This allowed for the utilization of FEM to combine the data from the literature reviews. The meta-analysis showed significantly higher OS rates in the experimental group (OR = 2.28, 95% CI (1.48–3.50, 0.0002)), as depicted in Figure 2.

Figure 2 
                        Forest map of original 1-year OS comparison between test group and control group.
Figure 2

Forest map of original 1-year OS comparison between test group and control group.

3.3.1.2 ORR

In total, six articles conducted a comparison between the ORR of patients in the experimental group and the control group. The experimental group consisted of 284 cases, whereas the control group had 290 cases. A heterogeneity test was performed on the collected literature, and the results indicated that there was no statistical heterogeneity among the different studies. Therefore, a FEM was utilized to combine the data from these studies. The meta-analysis showed significantly higher ORR rates in the experimental group, with a statistically significant difference (OR = 3.05, 95% CI (2.10–4.43), P < 0.00001), as illustrated in Figure 3.

Figure 3 
                        Forest map of ORR comparison between test group and control group.
Figure 3

Forest map of ORR comparison between test group and control group.

3.3.1.3 DCR

A total of six studies were included in the analysis to compare the DCR of patients in the experimental group and the control group. The experimental group consisted of 284 cases, while the control group had 290 cases. Statistical tests were conducted to assess the heterogeneity of the included studies, and the results indicated no significant heterogeneity among them. Therefore, FEM was utilized to combine the data from these studies. The meta-analysis showed significantly higher DCR rates in the experimental group (OR = 3.53, 95% CI (2.41–5.18), P < 0.00001), as depicted in Figure 4.

Figure 4 
                        Forest map of DCR comparison between test group and control group.
Figure 4

Forest map of DCR comparison between test group and control group.

3.3.1.4 Progression-free survival (PFS)

The PFS of patients in the experimental group was compared to that in the control group in a total of three literatures. A total of 240 cases were included in the test group and 226 cases in the control group. The included literature underwent a heterogeneity test, which yielded a result of 0.0004, indicating statistical heterogeneity among the different studies. Therefore, a REM was utilized to combine the literature data. The meta-analysis showed significantly longer PFS rates in the experimental group (OR = 1.32, 95% CI (0.25–2.38), PP 0.02), as depicted in Figure 5.

Figure 5 
                        Forest map of PFS comparison between test group and control group.
Figure 5

Forest map of PFS comparison between test group and control group.

3.3.1.5 Adverse reaction

There were a total of four studies that conducted a comparison of adverse reactions between the experimental and control groups. The test group consisted of 313 cases, while the control group had 290 cases. Statistical heterogeneity testing was performed on the included studies, yielding a result of 0.004%, indicating the presence of significant heterogeneity among them. Therefore, a REM was employed to combine the data from these studies. The meta-analysis results revealed no statistically significant difference in adverse reactions between the test group and control group (P > 0.05), as illustrated in Figure 6.

Figure 6 
                        Forest map of adverse reactions between the test group and the control group.
Figure 6

Forest map of adverse reactions between the test group and the control group.

3.3.2 Immunity

3.3.2.1 CD4+

A total of eight studies were conducted to compare the CD4+ levels between the experimental and control groups. The test group consisted of 470 cases, while the control group had 455 cases. A heterogeneity test was conducted on the included studies, revealing statistical heterogeneity among them. Hence, a REM was employed to combine the data from these studies. The meta-analysis showed significantly higher CD4+ rates in the experimental group (OR = 4.43, 95% CI (1.78–7.08), PSA 0.001), as illustrated in Figure 7.

Figure 7 
                        Forest map of CD4+ comparison between test group and control group.
Figure 7

Forest map of CD4+ comparison between test group and control group.

3.3.2.2 CD8+

A total of five articles conducted a comparison between the experimental group and the control group regarding the CD8+ level. Among these studies, the number of cases in the experimental group was 342, while in the control group it was 328. The pooled data were subjected to a heterogeneity test, which revealed that there was a significant variability among the different literature studies. To address this, the REM was employed for data synthesis. The meta-analysis showed significantly lower CD8+ rates in the experimental group (OR = −2.80, 95% CI (−5.03 to 0.57), PP01), as illustrated in Figure 8.

Figure 8 
                        Forest map of CD8+ comparison between test group and control group.
Figure 8

Forest map of CD8+ comparison between test group and control group.

3.3.2.3 CD4+/CD8+

A total of eight research papers conducted a comparison between the experimental group and the control group in terms of the CD4+/CD8+ level. Among them, the test group consisted of 470 cases, while the control group consisted of 455 cases. Statistical heterogeneity was detected among the included papers, indicating variations in the study results. Therefore, a REM was utilized to combine the data from different studies. The meta-analysis showed significantly higher CD4+/CD8+ level rates in the experimental group (OR = 0.41, 95% CI (0.20–0.63), P < 0.0001). This finding is depicted in Figure 9.

Figure 9 
                        Forest map of CD4+/CD8+ comparison between test group and control group.
Figure 9

Forest map of CD4+/CD8+ comparison between test group and control group.

3.4 Sensitivity analysis and literature bias test

Sensitivity analysis was conducted using ORR as a case study to validate the reliability of the findings. By excluding the literature with the highest proportion and integrating the literature effect again, the OR (95% CI) was found to be 3.72 (2.34–5.90), P < 0.00001. The credibility of the study results can be observed in Figure 10.

Figure 10 
                  Forest map of sensitivity analysis between test group and control group.
Figure 10

Forest map of sensitivity analysis between test group and control group.

The outcome indicators examined in this study presented inherent biases, and the findings demonstrated an asymmetrical pattern in the funnel plot, suggesting the presence of bias. Refer Figure 11 for visual representation.

Figure 11 
                  Funnel diagram of test group and control group.
Figure 11

Funnel diagram of test group and control group.

4 Discussion

Currently, there is a debate surrounding the application of combined immunotherapy and chemotherapy in individuals diagnosed with NSCLC. Therefore, this study aims to quantitatively assess and analyze previous research on the effectiveness and safety of combining immunotherapy and chemotherapy, in order to shed light on this controversial issue.

The results obtained from meta-analysis revealed that the immunotherapy combined with chemotherapy group exhibited significantly higher rates of 1-year OS, ORR, DCR, and PFS compared to the control group. Conversely, there was no notable variation in adverse reactions between the two groups. Concerning immune function, the experimental group demonstrated notably higher levels of CD4+ and CD4+/CD8+ in comparison to the control group. However, the experimental group displayed a lower level of CD8+ compared to the control group. Furthermore, sensitivity analysis demonstrated the stability and reliability of the combined effect (OR (95% CI) 3.72 (2.34–5.90), P < 0.00001). The results derived from the funnel chart pointed to the existence of publication bias. In order to reduce the sources of bias analysis, it is recommended to apply more stringent inclusion and exclusion criteria in future studies. In addition, expanding the source of databases, not limited to Chinese and English databases, can also be one of the important ways to reduce bias analysis.

There are several limitations to this study. First, the study includes a small sample size and a limited number of relevant literature sources, which restricts the support from multicenter and large sample studies. Second, individual patients exhibit variations in disease state and progression, leading to potential confounding factors. Lastly, the usage of different immune or chemotherapy regimens and treatment durations may introduce bias into the results of this study.

To summarize, the combination of chemotherapy and immunotherapy exhibits the potential to enhance both survival rates and clinical effectiveness, without the concomitant rise in severe adverse reactions. Additionally, there seems to be a tendency toward enhancing immune function, thereby rendering this approach highly suitable for clinical implementation. Therefore, it is suggested that the combination of chemotherapy and immunotherapy can be used clinically for patients with NSCLC, which can improve the potential of survival and clinical efficacy, and will not be accompanied by an increase in serious adverse reactions. Nevertheless, specific suggestions on the need for more randomized controlled trials with a larger sample size or suggestions for standardizing chemotherapy/immunotherapy combinations in future trials could be added.

Acknowledgments

Not applicable.

  1. Funding information: The authors state no funding involved.

  2. Author contributions: Wugang Zhu and Xiaolan Lu: conceptualization, methodology, writing – original draft preparation. Wenjing Xu, Degan Liu, and Lei Wan: data analysis. All authors read and approved the final manuscript.

  3. Conflict of interest: The authors state no conflict of interest.

  4. Data availability statement: All data generated or analyzed during this study are included in this published article. The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

References

[1] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA-Cancer J Clin. 2023;73(1):17–48. 10.3322/caac.21763.Suche in Google Scholar PubMed

[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2021;71(3):209–49. 10.3322/caac.21660.Suche in Google Scholar PubMed

[3] Chen Q, Guo Z, Liu S, Quan P, Cao X, Guo L, et al. The cancer incidence and mortality among children and adolescents during the period of 2010–2014 in Henan Province, China. Cancer Med-US. 2019;8(2):814–23. 10.1002/cam4.1952.Suche in Google Scholar PubMed PubMed Central

[4] Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54. 10.1038/nature25183.Suche in Google Scholar PubMed

[5] Han RX, Liu X, Pan P, Jia YJ, Yu JC. Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis. PLoS One. 2014;9(9):e108958. 10.1371/journal.pone.0108958.Suche in Google Scholar PubMed PubMed Central

[6] Vrana D, Matzenauer M, Neoral C, Aujesky R, Vrba R, Melichar B, et al. From tumor immunology to immunotherapy in gastric and esophageal cancer. Int J Mol Sci. 2018;20(1):13. 10.3390/ijms20010013.Suche in Google Scholar PubMed PubMed Central

[7] Simsek M, Tekin SB, Bilici M. Immunological agents used in cancer treatment. Eurasian J Med. 2019;51(1):90–4. 10.5152/eurasianjmed.2018.18194.Suche in Google Scholar PubMed PubMed Central

[8] Dall’Olio FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N, et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2022;19(2):75–90. 10.1038/s41571-021-00564-3.Suche in Google Scholar PubMed

[9] Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–80. 10.1038/s41568-020-0285-7.Suche in Google Scholar PubMed

[10] Ulas EB, Dickhoff C, Schneiders FL, Senan S, Bahce I. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. Esmo Open. 2021;6(5):100244. 10.1016/j.esmoop.2021.100244.Suche in Google Scholar PubMed PubMed Central

[11] Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67. 10.1182/blood-2017-06-741033.Suche in Google Scholar PubMed PubMed Central

[12] Yang L, Ren B, Li H, Yu J, Cao S, Hao X, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immun. 2013;62(1):65–73. 10.1007/s00262-012-1311-8.Suche in Google Scholar PubMed PubMed Central

[13] Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immun. 2011;60(10):1497–502. 10.1007/s00262-011-1060-0.Suche in Google Scholar PubMed PubMed Central

[14] Zhu ZQ, Li W. Efficacy of DC-CIK immunotherapy combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Jilin Med. 2019;40(8):1799–800.Suche in Google Scholar

[15] Liu ZG, Han JH. Effect of DC-CIK biological immunotherapy combined with chemoradiotherapy on advanced non-small cell lung cancer. Chin Natl Health Med. 2018;30(15):28–30.Suche in Google Scholar

[16] Zhang HJ, Yu ZD, Zhang YP, Zhang HB. Effect of immunotherapy combined with chemotherapy in treatment of advanced non-small cell lung cancer. Chin Med Guidel. 2020;18(13):69–70.Suche in Google Scholar

[17] He J, Long XY, Wang Y, Su XL, Jiang B, Wang J. Efficacy and safety of PD-1/PD-L1 immunotherapy combined with docetaxel chemotherapy in the treatment of advanced retreatable NSCLC. West Med. 2002;34(02):289–92.Suche in Google Scholar

[18] Yang JY, Wu H, Deng YL, Chen XL, Qian J. Efficacy and safety of PD-1/PD-L1 inhibitors in patients with advanced driver negative non-small cell lung cancer. Clin Med Res Pract. 2023;8(34):44–8.Suche in Google Scholar

[19] Zhao JJ, Li L, Tan YF, Zhao B. Effects of chemotherapy combined with immunochemotherapy on inflammatory factors and immune cells in patients with non-small cell lung cancer. J Pract Cancer. 2022;37(6):917–21.Suche in Google Scholar

[20] Sun LL, Liu XF, Fu YR. Clinical study of Carrilizumab combined with platinum in the treatment of non-small cell lung cancer. J Med Forum. 2023;44(20):44–9.Suche in Google Scholar

[21] Li L, Hu X, Cao ZG. Clinical efficacy of carrilizumab combined with chemotherapy in the treatment of elderly patients with non-small cell lung cancer and its effect on serum CY211 and MMP-9 expression. J Clin Exp Med. 2023;22(22):2380–3.Suche in Google Scholar

[22] Chen M, Xie H. The value of immunotherapy in combination with platinum-containing two-drug chemotherapy for resectable non-small cell lung cancer. J Community Med. 2023;21(5):240–4.Suche in Google Scholar

[23] Sun XY. Effectiveness of immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer. Syst Med. 2022;7(19):68–71.Suche in Google Scholar

[24] He SY, Zhang M, Xu Z, Lu XL, Zuo Y. Effect of sintilimab combined with chemotherapy in the treatment of non-small cell lung cancer andits influence on immune function indexes. China Pract Med. 2021;16(24):12–5.Suche in Google Scholar

[25] Pan EY, Xia Q. Effect of Bevacizumab combined with chemotherapy in the treatment of non-small cell lung cancerand its influence on T cell subsets and immune function. China Med Her. 2021;18(29):118–21.Suche in Google Scholar

[26] Shi YY, Lian RF. Effect of chemotherapy combined with immunotherapy and chemotherapy alone in the treatment of advanced non-small cell lung cancer. Chin Sci Technol J Database (full-text Ed) Med Hyg. 2023;2023(12):0043–5.Suche in Google Scholar

[27] Zhang JB, Lu Z, Zhou XY. Efficacy of Tirellizumab combined with GP chemotherapy in the treatment of advanced NSCLC and its effect on immune function. Chin J Health Care Med. 2022;24(3):252–4.Suche in Google Scholar

Received: 2024-07-08
Revised: 2024-09-23
Accepted: 2024-10-01
Published Online: 2025-08-07

© 2025 the author(s), published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Research Articles
  2. Network pharmacological analysis and in vitro testing of the rutin effects on triple-negative breast cancer
  3. Impact of diabetes on long-term survival in elderly liver cancer patients: A retrospective study
  4. Knockdown of CCNB1 alleviates high glucose-triggered trophoblast dysfunction during gestational diabetes via Wnt/β-catenin signaling pathway
  5. Risk factors for severe adverse drug reactions in hospitalized patients
  6. Analysis of the effect of ALA-PDT on macrophages in footpad model of mice infected with Fonsecaea monophora based on single-cell sequencing
  7. Development and validation of headspace gas chromatography with a flame ionization detector method for the determination of ethanol in the vitreous humor
  8. CMSP exerts anti-tumor effects on small cell lung cancer cells by inducing mitochondrial dysfunction and ferroptosis
  9. Predictive value of plasma sB7-H3 and YKL-40 in pediatric refractory Mycoplasma pneumoniae pneumonia
  10. Antiangiogenic potential of Elaeagnus umbellata extracts and molecular docking study by targeting VEGFR-2 pathway
  11. Comparison of the effectiveness of nurse-led preoperative counseling and postoperative follow-up care vs standard care for patients with gastric cancer
  12. Comparing the therapeutic efficacy of endoscopic minimally invasive surgery and traditional surgery for early-stage breast cancer: A meta-analysis
  13. Adhered macrophages as an additional marker of cardiomyocyte injury in biopsies of patients with dilated cardiomyopathy
  14. Association between statin administration and outcome in patients with sepsis: A retrospective study
  15. Exploration of the association between estimated glucose disposal rate and osteoarthritis in middle-aged and older adults: An analysis of NHANES data from 2011 to 2018
  16. A comparative analysis of the binary and multiclass classified chest X-ray images of pneumonia and COVID-19 with ML and DL models
  17. Lysophosphatidic acid 2 alleviates deep vein thrombosis via protective endothelial barrier function
  18. Transcription factor A, mitochondrial promotes lymph node metastasis and lymphangiogenesis in epithelial ovarian carcinoma
  19. Serum PM20D1 levels are associated with nutritional status and inflammatory factors in gastric cancer patients undergoing early enteral nutrition
  20. Hydromorphone reduced the incidence of emergence agitation after adenotonsillectomy in children with obstructive sleep apnea: A randomized, double-blind study
  21. Vitamin D replacement therapy may regulate sleep habits in patients with restless leg syndrome
  22. The first-line antihypertensive nitrendipine potentiated the therapeutic effect of oxaliplatin by downregulating CACNA1D in colorectal cancer
  23. Health literacy and health-related quality of life: The mediating role of irrational happiness
  24. Modulatory effects of Lycium barbarum polysaccharide on bone cell dynamics in osteoporosis
  25. Mechanism research on inhibition of gastric cancer in vitro by the extract of Pinellia ternata based on network pharmacology and cellular metabolomics
  26. Examination of the causal role of immune cells in non-alcoholic fatty liver disease by a bidirectional Mendelian randomization study
  27. Clinical analysis of ten cases of HIV infection combined with acute leukemia
  28. Investigating the cardioprotective potential of quercetin against tacrolimus-induced cardiotoxicity in Wistar rats: A mechanistic insights
  29. Clinical observation of probiotics combined with mesalazine and Yiyi Baitouweng Decoction retention enema in treating mild-to-moderate ulcerative colitis
  30. Diagnostic value of ratio of blood inflammation to coagulation markers in periprosthetic joint infection
  31. Sex-specific associations of sex hormone binding globulin and risk of bladder cancer
  32. Core muscle strength and stability-oriented breathing training reduces inter-recti distance in postpartum women
  33. The ERAS nursing care strategy for patients undergoing transsphenoidal endoscopic pituitary tumor resection: A randomized blinded controlled trial
  34. The serum IL-17A levels in patients with traumatic bowel rupture post-surgery and its predictive value for patient prognosis
  35. Impact of Kolb’s experiential learning theory-based nursing on caregiver burden and psychological state of caregivers of dementia patients
  36. Analysis of serum NLR combined with intraoperative margin condition to predict the prognosis of cervical HSIL patients undergoing LEEP surgery
  37. Commiphora gileadensis ameliorate infertility and erectile dysfunction in diabetic male mice
  38. The correlation between epithelial–mesenchymal transition classification and MMP2 expression of circulating tumor cells and prognosis of advanced or metastatic nasopharyngeal carcinoma
  39. Tetrahydropalmatine improves mitochondrial function in vascular smooth muscle cells of atherosclerosis in vitro by inhibiting Ras homolog gene family A/Rho-associated protein kinase-1 signaling pathway
  40. A cross-sectional study: Relationship between serum oxidative stress levels and arteriovenous fistula maturation in maintenance dialysis patients
  41. A comparative analysis of the impact of repeated administration of flavan 3-ol on brown, subcutaneous, and visceral adipose tissue
  42. Identifying early screening factors for depression in middle-aged and older adults: A cohort study
  43. Perform tumor-specific survival analysis for Merkel cell carcinoma patients undergoing surgical resection based on the SEER database by constructing a nomogram chart
  44. Unveiling the role of CXCL10 in pancreatic cancer progression: A novel prognostic indicator
  45. High-dose preoperative intraperitoneal erythropoietin and intravenous methylprednisolone in acute traumatic spinal cord injuries following decompression surgeries
  46. RAB39B: A novel biomarker for acute myeloid leukemia identified via multi-omics and functional validation
  47. Impact of peripheral conditioning on reperfusion injury following primary percutaneous coronary intervention in diabetic and non-diabetic STEMI patients
  48. Clinical efficacy of azacitidine in the treatment of middle- and high-risk myelodysplastic syndrome in middle-aged and elderly patients: A retrospective study
  49. The effect of ambulatory blood pressure load on mitral regurgitation in continuous ambulatory peritoneal dialysis patients
  50. Expression and clinical significance of ITGA3 in breast cancer
  51. Single-nucleus RNA sequencing reveals ARHGAP28 expression of podocytes as a biomarker in human diabetic nephropathy
  52. rSIG combined with NLR in the prognostic assessment of patients with multiple injuries
  53. Toxic metals and metalloids in collagen supplements of fish and jellyfish origin: Risk assessment for daily intake
  54. Exploring causal relationship between 41 inflammatory cytokines and marginal zone lymphoma: A bidirectional Mendelian randomization study
  55. Gender beliefs and legitimization of dating violence in adolescents
  56. Effect of serum IL-6, CRP, and MMP-9 levels on the efficacy of modified preperitoneal Kugel repair in patients with inguinal hernia
  57. Effect of smoking and smoking cessation on hematological parameters in polycythemic patients
  58. Pathogen surveillance and risk factors for pulmonary infection in patients with lung cancer: A retrospective single-center study
  59. Necroptosis of hippocampal neurons in paclitaxel chemotherapy-induced cognitive impairment mediates microglial activation via TLR4/MyD88 signaling pathway
  60. Celastrol suppresses neovascularization in rat aortic vascular endothelial cells stimulated by inflammatory tenocytes via modulating the NLRP3 pathway
  61. Cord-lamina angle and foraminal diameter as key predictors of C5 palsy after anterior cervical decompression and fusion surgery
  62. GATA1: A key biomarker for predicting the prognosis of patients with diffuse large B-cell lymphoma
  63. Influencing factors of false lumen thrombosis in type B aortic dissection: A single-center retrospective study
  64. MZB1 regulates the immune microenvironment and inhibits ovarian cancer cell migration
  65. Integrating experimental and network pharmacology to explore the pharmacological mechanisms of Dioscin against glioblastoma
  66. Trends in research on preterm birth in twin pregnancy based on bibliometrics
  67. Four-week IgE/baseline IgE ratio combined with tryptase predicts clinical outcome in omalizumab-treated children with moderate-to-severe asthma
  68. Single-cell transcriptomic analysis identifies a stress response Schwann cell subtype
  69. Acute pancreatitis risk in the diagnosis and management of inflammatory bowel disease: A critical focus
  70. Effect of subclinical esketamine on NLRP3 and cognitive dysfunction in elderly ischemic stroke patients
  71. Interleukin-37 mediates the anti-oral tumor activity in oral cancer through STAT3
  72. CA199 and CEA expression levels, and minimally invasive postoperative prognosis analysis in esophageal squamous carcinoma patients
  73. Efficacy of a novel drainage catheter in the treatment of CSF leak after posterior spine surgery: A retrospective cohort study
  74. Comprehensive biomedicine assessment of Apteranthes tuberculata extracts: Phytochemical analysis and multifaceted pharmacological evaluation in animal models
  75. Relation of time in range to severity of coronary artery disease in patients with type 2 diabetes: A cross-sectional study
  76. Dopamine attenuates ethanol-induced neuronal apoptosis by stimulating electrical activity in the developing rat retina
  77. Correlation between albumin levels during the third trimester and the risk of postpartum levator ani muscle rupture
  78. Factors associated with maternal attention and distraction during breastfeeding and childcare: A cross-sectional study in the west of Iran
  79. Mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experiments
  80. The law on oncological oblivion in the Italian and European context: How to best uphold the cancer patients’ rights to privacy and self-determination?
  81. The prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and prognostic nutritional index for survival in patients with colorectal cancer
  82. Factors affecting the measurements of peripheral oxygen saturation values in healthy young adults
  83. Comparison and correlations between findings of hysteroscopy and vaginal color Doppler ultrasonography for detection of uterine abnormalities in patients with recurrent implantation failure
  84. The effects of different types of RAGT on balance function in stroke patients with low levels of independent walking in a convalescent rehabilitation hospital
  85. Causal relationship between asthma and ankylosing spondylitis: A bidirectional two-sample univariable and multivariable Mendelian randomization study
  86. Correlations of health literacy with individuals’ understanding and use of medications in Southern Taiwan
  87. Correlation of serum calprotectin with outcome of acute cerebral infarction
  88. Comparison of computed tomography and guided bronchoscopy in the diagnosis of pulmonary nodules: A systematic review and meta-analysis
  89. Curdione protects vascular endothelial cells and atherosclerosis via the regulation of DNMT1-mediated ERBB4 promoter methylation
  90. The identification of novel missense variant in ChAT gene in a patient with gestational diabetes denotes plausible genetic association
  91. Molecular genotyping of multi-system rare blood types in foreign blood donors based on DNA sequencing and its clinical significance
  92. Exploring the role of succinyl carnitine in the association between CD39⁺ CD4⁺ T cell and ulcerative colitis: A Mendelian randomization study
  93. Dexmedetomidine suppresses microglial activation in postoperative cognitive dysfunction via the mmu-miRNA-125/TRAF6 signaling axis
  94. Analysis of serum metabolomics in patients with different types of chronic heart failure
  95. Diagnostic value of hematological parameters in the early diagnosis of acute cholecystitis
  96. Pachymaran alleviates fat accumulation, hepatocyte degeneration, and injury in mice with nonalcoholic fatty liver disease
  97. Decrease in CD4 and CD8 lymphocytes are predictors of severe clinical picture and unfavorable outcome of the disease in patients with COVID-19
  98. METTL3 blocked the progression of diabetic retinopathy through m6A-modified SOX2
  99. The predictive significance of anti-RO-52 antibody in patients with interstitial pneumonia after treatment of malignant tumors
  100. Exploring cerebrospinal fluid metabolites, cognitive function, and brain atrophy: Insights from Mendelian randomization
  101. Development and validation of potential molecular subtypes and signatures of ocular sarcoidosis based on autophagy-related gene analysis
  102. Widespread venous thrombosis: Unveiling a complex case of Behçet’s disease with a literature perspective
  103. Uterine fibroid embolization: An analysis of clinical outcomes and impact on patients’ quality of life
  104. Discovery of lipid metabolism-related diagnostic biomarkers and construction of diagnostic model in steroid-induced osteonecrosis of femoral head
  105. Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer
  106. Enhancing chronic back pain management: A comparative study of ultrasound–MRI fusion guidance for paravertebral nerve block
  107. Peptide CCAT1-70aa promotes hepatocellular carcinoma proliferation and invasion via the MAPK/ERK pathway
  108. Electroacupuncture-induced reduction of myocardial ischemia–reperfusion injury via FTO-dependent m6A methylation modulation
  109. Hemorrhoids and cardiovascular disease: A bidirectional Mendelian randomization study
  110. Cell-free adipose extract inhibits hypertrophic scar formation through collagen remodeling and antiangiogenesis
  111. HALP score in Demodex blepharitis: A case–control study
  112. Assessment of SOX2 performance as a marker for circulating cancer stem-like cells (CCSCs) identification in advanced breast cancer patients using CytoTrack system
  113. Risk and prognosis for brain metastasis in primary metastatic cervical cancer patients: A population-based study
  114. Comparison of the two intestinal anastomosis methods in pediatric patients
  115. Factors influencing hematological toxicity and adverse effects of perioperative hyperthermic intraperitoneal vs intraperitoneal chemotherapy in gastrointestinal cancer
  116. Endotoxin tolerance inhibits NLRP3 inflammasome activation in macrophages of septic mice by restoring autophagic flux through TRIM26
  117. Lateral transperitoneal laparoscopic adrenalectomy: A single-centre experience of 21 procedures
  118. Petunidin attenuates lipopolysaccharide-induced retinal microglia inflammatory response in diabetic retinopathy by targeting OGT/NF-κB/LCN2 axis
  119. Procalcitonin and C-reactive protein as biomarkers for diagnosing and assessing the severity of acute cholecystitis
  120. Factors determining the number of sessions in successful extracorporeal shock wave lithotripsy patients
  121. Development of a nomogram for predicting cancer-specific survival in patients with renal pelvic cancer following surgery
  122. Inhibition of ATG7 promotes orthodontic tooth movement by regulating the RANKL/OPG ratio under compression force
  123. A machine learning-based prognostic model integrating mRNA stemness index, hypoxia, and glycolysis‑related biomarkers for colorectal cancer
  124. Glutathione attenuates sepsis-associated encephalopathy via dual modulation of NF-κB and PKA/CREB pathways
  125. 10.1515/med-2025-1200
  126. Review Articles
  127. The effects of enhanced external counter-pulsation on post-acute sequelae of COVID-19: A narrative review
  128. Diabetes-related cognitive impairment: Mechanisms, symptoms, and treatments
  129. Microscopic changes and gross morphology of placenta in women affected by gestational diabetes mellitus in dietary treatment: A systematic review
  130. Review of mechanisms and frontier applications in IL-17A-induced hypertension
  131. Research progress on the correlation between islet amyloid peptides and type 2 diabetes mellitus
  132. The safety and efficacy of BCG combined with mitomycin C compared with BCG monotherapy in patients with non-muscle-invasive bladder cancer: A systematic review and meta-analysis
  133. The application of augmented reality in robotic general surgery: A mini-review
  134. The effect of Greek mountain tea extract and wheat germ extract on peripheral blood flow and eicosanoid metabolism in mammals
  135. Neurogasobiology of migraine: Carbon monoxide, hydrogen sulfide, and nitric oxide as emerging pathophysiological trinacrium relevant to nociception regulation
  136. Plant polyphenols, terpenes, and terpenoids in oral health
  137. Laboratory medicine between technological innovation, rights safeguarding, and patient safety: A bioethical perspective
  138. End-of-life in cancer patients: Medicolegal implications and ethical challenges in Europe
  139. The maternal factors during pregnancy for intrauterine growth retardation: An umbrella review
  140. Intra-abdominal hypertension/abdominal compartment syndrome of pediatric patients in critical care settings
  141. PI3K/Akt pathway and neuroinflammation in sepsis-associated encephalopathy
  142. Screening of Group B Streptococcus in pregnancy: A systematic review for the laboratory detection
  143. Giant borderline ovarian tumours – review of the literature
  144. Leveraging artificial intelligence for collaborative care planning: Innovations and impacts in shared decision-making – A systematic review
  145. Cholera epidemiology analysis through the experience of the 1973 Naples epidemic
  146. Risk factors of frailty/sarcopenia in community older adults: Meta-analysis
  147. Supplement strategies for infertility in overweight women: Evidence and legal insights
  148. Case Reports
  149. Delayed graft function after renal transplantation
  150. Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature
  151. Diverse electrophysiological demyelinating features in a late-onset glycogen storage disease type IIIa case
  152. Giant right atrial hemangioma presenting with ascites: A case report
  153. Laser excision of a large granular cell tumor of the vocal cord with subglottic extension: A case report
  154. EsoFLIP-assisted dilation for dysphagia in systemic sclerosis: Highlighting the role of multimodal esophageal evaluation
  155. Rapid Communication
  156. Biological properties of valve materials using RGD and EC
  157. Letter to the Editor
  158. Role of enhanced external counterpulsation in long COVID
  159. Expression of Concern
  160. Expression of concern “A ceRNA network mediated by LINC00475 in papillary thyroid carcinoma”
  161. Expression of concern “Notoginsenoside R1 alleviates spinal cord injury through the miR-301a/KLF7 axis to activate Wnt/β-catenin pathway”
  162. Expression of concern “circ_0020123 promotes cell proliferation and migration in lung adenocarcinoma via PDZD8”
  163. Corrigendum
  164. Corrigendum to “Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism”
  165. Corrigendum to “Comparing the therapeutic efficacy of endoscopic minimally invasive surgery and traditional surgery for early-stage breast cancer: A meta-analysis”
  166. Corrigendum to “The progress of autoimmune hepatitis research and future challenges”
  167. Retraction
  168. Retraction of “miR-654-5p promotes gastric cancer progression via the GPRIN1/NF-κB pathway”
  169. Special Issue Advancements in oncology: bridging clinical and experimental research - Part II
  170. Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer
  171. Lathyrol affects the expression of AR and PSA and inhibits the malignant behavior of RCC cells
  172. The era of increasing cancer survivorship: Trends in fertility preservation, medico-legal implications, and ethical challenges
  173. Bone scintigraphy and positron emission tomography in the early diagnosis of MRONJ
  174. Meta-analysis of clinical efficacy and safety of immunotherapy combined with chemotherapy in non-small cell lung cancer
  175. Special Issue Computational Intelligence Methodologies Meets Recurrent Cancers - Part IV
  176. Exploration of mRNA-modifying METTL3 oncogene as momentous prognostic biomarker responsible for colorectal cancer development
  177. Special Issue The evolving saga of RNAs from bench to bedside - Part III
  178. Interaction and verification of ferroptosis-related RNAs Rela and Stat3 in promoting sepsis-associated acute kidney injury
  179. The mRNA MOXD1: Link to oxidative stress and prognostic significance in gastric cancer
  180. Special Issue Exploring the biological mechanism of human diseases based on MultiOmics Technology - Part II
  181. Dynamic changes in lactate-related genes in microglia and their role in immune cell interactions after ischemic stroke
  182. A prognostic model correlated with fatty acid metabolism in Ewing’s sarcoma based on bioinformatics analysis
  183. Special Issue Diabetes
  184. Nutritional risk assessment and nutritional support in children with congenital diabetes during surgery
  185. Correlation of the differential expressions of RANK, RANKL, and OPG with obesity in the elderly population in Xinjiang
  186. A discussion on the application of fluorescence micro-optical sectioning tomography in the research of cognitive dysfunction in diabetes
  187. A review of brain research on T2DM-related cognitive dysfunction
  188. Special Issue Biomarker Discovery and Precision Medicine
  189. CircASH1L-mediated tumor progression in triple-negative breast cancer: PI3K/AKT pathway mechanisms
Heruntergeladen am 25.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/med-2024-1071/html
Button zum nach oben scrollen